T. Rowe Price takes 6.2% stake in MapLight Therapeutics (MPLT)

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting beneficial ownership of 2,799,180 shares of MapLight Therapeutics Inc. common stock, representing 6.2% of the outstanding class as of the event date of 12/31/2025.

The firm indicates the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MapLight. It also expressly denies being the beneficial owner of the securities beyond what is reported in the filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MAPLIGHT THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

56565P103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 56565P103

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,709,846.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,726,298.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,799,180.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MAPLIGHT THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 56565P103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2799180
(b)	Percent of class: 6.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 7709846
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 7726298
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026

FAQ

What ownership stake in MPLT does T. Rowe Price report on this Schedule 13G?

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 2,799,180 shares of MapLight Therapeutics common stock, representing 6.2% of the class. This makes it a significant institutional holder above the 5% reporting threshold.

Why did T. Rowe Price file a Schedule 13G for MapLight Therapeutics (MPLT)?

T. Rowe Price filed a Schedule 13G because its beneficial ownership in MapLight Therapeutics common stock exceeded 5%. The firm characterizes the position as held in the ordinary course of business, without the purpose of changing or influencing control of the company.

What is the reported percentage of MapLight Therapeutics (MPLT) owned by T. Rowe Price?

T. Rowe Price reports owning 6.2% of MapLight Therapeutics’ outstanding common stock. This percentage is based on the 2,799,180 shares identified as beneficially owned as of the 12/31/2025 reporting event date in the Schedule 13G.

How does T. Rowe Price describe its intent regarding its MPLT shareholding?

T. Rowe Price states the securities were acquired and are held in the ordinary course of business, not to change or influence control of MapLight Therapeutics. It also notes the position is not part of any transaction aimed at exerting control over the issuer.

Does T. Rowe Price claim full beneficial ownership of its MPLT position?

T. Rowe Price expressly denies full beneficial ownership of the reported securities, even while listing 2,799,180 shares as beneficially owned. This type of disclaimer is common when shares may be held for clients or managed accounts rather than for the firm itself.